Popular Trials
Proton Beam Therapy
Intensity Modulated Proton Radiation for Brain & Spine Cancer
This trial is testing a new way to give proton radiation therapy for tumors in the brain and spine. The new way, called intensity modulated proton radiation therapy (IMPT), may be more accurate and have fewer side effects than the standard proton radiation therapy.
Popular Filters
Trials for Cancer Patients
CAR T-cell Therapy
TIL Therapy for Cancer
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
Alkylating agents
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
Trials for Rhabdomyosarcoma Patients
PARP Inhibitor
Olaparib + Temozolomide for Sarcoma
This trial is testing the safety of an investigational drug combo and what dose is appropriate. The drugs in the combo work by interfering with cancer cells' ability to repair DNA and thus continue dividing.
Trials for Metastatic Patients
CAR T-cell Therapy
FITC-E2 CAR T Cells + Folate-Fluorescein for Osteosarcoma
This trial tests a new treatment for patients with hard-to-treat or recurring osteosarcoma. It uses a special drug and modified immune cells to target and kill cancer cells. The patient's own immune cells are changed in a lab to better recognize cancer, and a drug helps these cells find and destroy the cancer.
Radioisotope
CLR 131 for Pediatric Cancer
This trial is testing CLR 131, a radioactive medicine designed to target and kill cancer cells. It is aimed at children, adolescents, and young adults whose cancers have returned or do not respond to other treatments. CLR 131 works by delivering radiation directly to the cancer cells, reducing harm to healthy cells.
Trials With No Placebo
CAR T-cell Therapy
FITC-E2 CAR T Cells + Folate-Fluorescein for Osteosarcoma
This trial tests a new treatment for patients with hard-to-treat or recurring osteosarcoma. It uses a special drug and modified immune cells to target and kill cancer cells. The patient's own immune cells are changed in a lab to better recognize cancer, and a drug helps these cells find and destroy the cancer.
CAR T-cell Therapy
TIL Therapy for Cancer
This trial tests a treatment using a patient's own immune cells to fight various cancers that haven't responded to other treatments or have come back. The immune cells are taken from the tumor, grown in a lab, and then reintroduced into the body to target and kill cancer cells. The study aims to see how well this approach works and how safe it is.
Alkylating agents
NK Cells + Cyclophosphamide + Etoposide for Solid Tumors
This trial is testing the side effects and best dose of cord blood-derived expanded allogeneic natural killer cells, given with cyclophosphamide and etoposide, to treat children and young adults with solid tumors.
View More Related Trials
Frequently Asked Questions
Introduction to bone cancer
What are the top hospitals conducting bone cancer research?
When it comes to the battle against bone cancer, several hospitals have emerged as leaders in conducting clinical trials that pave the way for innovative treatments. In sunny Miami, Nicklaus Children's Hospital is making strides with two active bone cancer trials and a total of two recorded trials dedicated to this challenging condition. The hospital initiated its first bone cancer trial in 2014—an important milestone in their ongoing commitment to improving patient outcomes. Meanwhile, M D Anderson Cancer Center in Houston stands alongside Nicklaus Children's Hospital with an equal number of active and all-time bone cancer trials, demonstrating their dedication to finding breakthroughs in this field since 2014.
Heading over to Colorado Springs, Penrose-Saint Francis Healthcare and Rocky Mountain Cancer Centers-Penrose are leading the charge against bone cancer by each conducting two active clinical trials while having completed a pair of earlier investigations focused on this complex disease. Both hospitals made significant contributions starting from 2014 when they embarked on their respective journeys towards advancing treatments for patients battling bone cancer.
Further north in Denver, Porter Adventist Hospital also joins the ranks with two ongoing clinical trials dedicated solely to combating bone cancer. Their commitment started back in 2014—pioneering efforts that continue to impact countless lives affected by this devastating illness.
These hospitals represent beacons of hope for those facing the challenges posed by bone cancer. Through relentless research efforts and groundbreaking clinical studies, these institutions emphasize that no stone should be left unturned when fighting such a formidable opponent as they strive toward developing more effective treatments and ultimately achieving brighter futures for patients worldwide.
Which are the best cities for bone cancer clinical trials?
In the realm of bone cancer clinical trials, several cities emerge as key players in research and treatment. Des Moines, Iowa takes the lead with 10 ongoing trials investigating diverse approaches such as Control arm, Stereotactic Radiosurgery, and 9-ING-41. Denver, Colorado follows closely with 9 active trials exploring interventions like Control arm and Stereotactic Radiosurgery. Springfield, Illinois also showcases its commitment to advancing bone cancer treatments through 6 studies focusing on Stereotactic Radiosurgery and Control arm among others. Meanwhile, Chicago, Illinois and Colorado Springs, Colorado contribute to the field with their respective investigations into promising methods like Stereotactic Radiosurgery and Control arm. These cities offer valuable opportunities for individuals seeking participation in cutting-edge bone cancer clinical trials that have the potential to shape future treatment options positively.
Which are the top treatments for bone cancer being explored in clinical trials?
In the world of bone cancer research, several treatments are currently being explored in clinical trials. One standout is 18F-sodium fluoride, with one active trial and a total of one trial dedicated to bone cancer since its listing in 2008. Another contender is tranexamic acid, also undergoing one active trial and two all-time bone cancer trials after being introduced in 2013. Lastly, there's 9-ING-41—an up-and-comer—currently involved in one ongoing trial for bone cancer since its debut in 2019. These innovative treatments hold promise for improving the lives of patients battling this challenging disease.
What are the most recent clinical trials for bone cancer?
In the realm of bone cancer research, recent clinical trials have offered promising prospects for improved treatments. One notable study is UB_TT170, a Phase 1 trial that became available on 5/20/2022. Additionally, Dose Level 1, another Phase 1 trial introduced on 4/5/2022 demonstrates potential benefits for patients with bone cancer. Moreover, Tranexamic Acid has undergone a Phase 3 clinical trial which commenced on 1/29/2021 and brings hope in advancing treatment options further. These ongoing investigations underscore the dedication to finding innovative solutions to combat this challenging disease and offer renewed optimism for those affected by bone cancer.
What bone cancer clinical trials were recently completed?
A notable clinical trial in the field of bone cancer research has recently concluded, marking a significant step forward in understanding and treating this challenging disease. In November 2017, Amgen successfully completed a trial investigating Denosumab (Cohort A) as a potential therapy for bone cancer. This study contributes valuable insights into the efficacy and safety of Denosumab in addressing the unique challenges posed by bone cancers. The completion of this trial represents an important milestone in ongoing efforts to improve treatments and outcomes for patients dealing with these complex malignancies.